Table 2.
Physical signs, laboratory results, and treatments in patients admitted with heart failure categorized by presence of worsening renal function (WRF) during hospitalization (n = 301).
| Factors | No WRF n = 219 |
WRF n = 82 |
p Value |
|---|---|---|---|
| Systolic blood pressure, mmHg | 150 (34) | 156 (39) | .300 |
| Diastolic blood pressure, mmHg | 82 (22) | 85 (22) | .169 |
| Heart rate, bpm | 82 (25) | 90 (23) | .437 |
| Oxygen saturation, % | 91 (9) | 89 (10) | .080 |
| Hemoglobin, g/% | 11.3 (2.5) | 11.1 (2.3) | .436 |
| Serum Cr, mg/dL | 1.58 (1.36) | 1.79 (1.34) | .050 |
| Serum sodium, mEq/L | 136 (5) | 136 (5) | .746 |
| BNP, pg/mL | 9212 (10160) | 17646 (26402) | .037 |
| Ejection fraction, % | 47 (17) | 47 (18) | .739 |
| Ejection fraction ≤40, n (%) | 80 (36.53) | 36 (43.90) | .287 |
| Net balance/day, ml | −948.45 (1262.15) | −442.49 (973.12) | <.001 |
| Intravenous furosemide, mg | 183 (472) | 397 (1117) | .078 |
| Oral furosemide, mg | 76 (183) | 68 (169) | .563 |
| Total dose of furosemide, mg | 259 (561) | 465 (1144) | .436 |
| Intravenous inotropic agent, n (%) | 18 (8.22) | 13 (15.85) | .058 |
| Intravenous nitroglycerin, n (%) | 33 (15.07) | 13 (15.85) | .859 |
| Thiazide use, n (%) | 4 (1.83) | 0 | .578 |
| Dose, mg | 34.37 (11.96) | 0 | NA |
| Spironolactone, n (%) | 12 (5.48) | 3 (3.66) | .767 |
| Dose, mg | 71.67 (77.10) | 91.66 (94.64) | .884 |
| ACEI/ARB, n (%) | 89 (38.81) | 28 (34.15) | .505 |
| CCB, n (%) | 69 (31.51) | 23 (28.05) | .673 |
| Betablocker, n (%) | 137 (62.56) | 39 (47.56) | .025 |
| Nephrotoxic agent, n (%) | |||
| Contrast media | 3 (1.37) | 0 | .565 |
| Antibiotic | 6 (2.74) | 2 (2.44) | .999 |
| NSAIDs | 1 (0.46) | 0 | .999 |
Data presented as mean (SD) unless indicated otherwise; BNP: B-type natriuretic peptide; ACEI: angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; NYHA: New York Heart Association; FC: Functional Classification; fluid therapy included both oral and intravenous forms.